Martin Johansson
Amministratore Delegato presso Glactone Pharma AB
Profilo
Martin Johansson is the founder of Glactone Pharma AB, which he founded in 2012 and where he holds the title of Chief Executive Officer.
He is currently an Associate Professor at the University of Lund.
Previously, he worked at Respiratorius AB from 2006 to 2011 as a Manager-Chemistry.
Posizioni attive di Martin Johansson
| Società | Posizione | Inizio |
|---|---|---|
| University of Lund | Corporate Officer/Principal | - |
Glactone Pharma AB
 Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Amministratore Delegato | 01/01/2012 |
Precedenti posizioni note di Martin Johansson
| Società | Posizione | Fine |
|---|---|---|
Respiratorius AB
 Respiratorius AB Pharmaceuticals: MajorHealth Technology Respiratorius AB engages in the development of drug candidates for Chronic Obstructive Pulmonary Disease, asthma, and cancer. The company was founded by Lars Christer Fedrik Fåhraeus and Staffan Skogwall in 1999 and is headquartered in Lund, Sweden. | Direttore Tecnico/Scientifico/R&S | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
 | Health Technology |
| Aziende private | 1 |
|---|---|
Glactone Pharma AB
Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Martin Johansson
